134 related articles for article (PubMed ID: 26935769)
1. Omacetaxine mepesuccinate induces apoptosis and cell cycle arrest, promotes cell differentiation, and reduces telomerase activity in diffuse large B‑cell lymphoma cells.
Zhang L; Chen Z; Zuo W; Zhu X; Li Y; Liu X; Wei X
Mol Med Rep; 2016 Apr; 13(4):3092-100. PubMed ID: 26935769
[TBL] [Abstract][Full Text] [Related]
2. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
3. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
4. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
5. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.
Allan EK; Holyoake TL; Craig AR; Jørgensen HG
Leukemia; 2011 Jun; 25(6):985-94. PubMed ID: 21468038
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
[TBL] [Abstract][Full Text] [Related]
7. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Narayanan V; Gutman JA; Pollyea DA; Jimeno A
Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
[TBL] [Abstract][Full Text] [Related]
8. Metabolite profiling of
Nijenhuis CM; Lucas L; Rosing H; Robertson P; Hellriegel ET; Schellens JH; Beijnen AJ
Xenobiotica; 2016 Dec; 46(12):1122-1132. PubMed ID: 26998885
[TBL] [Abstract][Full Text] [Related]
9. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J; Mita A; Stephenson J; Mita MM; Sarantopoulos J; Padmanabhan-Iyer S; Nanda N; Gleich L; Benichou AC; Craig A
Cancer Chemother Pharmacol; 2013 Jan; 71(1):35-41. PubMed ID: 23053254
[TBL] [Abstract][Full Text] [Related]
11. U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia.
Alvandi F; Kwitkowski VE; Ko CW; Rothmann MD; Ricci S; Saber H; Ghosh D; Brown J; Pfeiler E; Chikhale E; Grillo J; Bullock J; Kane R; Kaminskas E; Farrell AT; Pazdur R
Oncologist; 2014 Jan; 19(1):94-9. PubMed ID: 24309980
[TBL] [Abstract][Full Text] [Related]
12. Storage and transport of reconstituted omacetaxine mepesuccinate: Considerations for home administration.
Parikh A; van de Rijn J; Melville C; Sarkari M; Peltier S; McKean R
J Oncol Pharm Pract; 2018 Apr; 24(3):201-208. PubMed ID: 29284358
[TBL] [Abstract][Full Text] [Related]
13. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH; Gorman SH; Burke SM; Campbell DA; Chapple MW; Yousey TH; Mulvana DE
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():152-9. PubMed ID: 26319804
[TBL] [Abstract][Full Text] [Related]
14. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
[TBL] [Abstract][Full Text] [Related]
15. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE; Khoury HJ; Akard L; Rea D; Kantarjian H; Baccarani M; Leonoudakis J; Craig A; Benichou AC; Cortes J
Haematologica; 2013 Jul; 98(7):e78-9. PubMed ID: 23753022
[No Abstract] [Full Text] [Related]
16. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.
Wetzler M; Kantarjian HM; Nicolini FE; Lipton JH; Akard L; Baccarani M; Khoury HJ; Li E; Munteanu M; Cortes J
Blood Cancer J; 2015 Dec; 5(12):e376. PubMed ID: 26657200
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.
Nijenhuis CM; Hellriegel E; Beijnen JH; Hershock D; Huitema AD; Lucas L; Mergui-Roelvink M; Munteanu M; Rabinovich-Guilatt L; Robertson P; Rosing H; Spiegelstein O; Schellens JH
Invest New Drugs; 2016 Oct; 34(5):565-74. PubMed ID: 27221729
[TBL] [Abstract][Full Text] [Related]
19. Decreased RNA‑binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B‑cell lymphoma cells by regulating the p53 signaling pathway.
Cui Y; Wen Y; Lv C; Zhao D; Yang Y; Qiu H; Wang C
Mol Med Rep; 2022 Sep; 26(3):. PubMed ID: 35894142
[TBL] [Abstract][Full Text] [Related]
20. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
Novotny L; Al-Tannak NF; Hunakova L
Neoplasma; 2016; 63(4):495-503. PubMed ID: 27268912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
